vs
EXACT SCIENCES CORP（EXAS）与Liberty Energy Inc.（LBRT）财务数据对比。点击上方公司名可切换其他公司
Liberty Energy Inc.的季度营收约是EXACT SCIENCES CORP的1.2倍（$1.0B vs $878.4M），Liberty Energy Inc.净利率更高（2.2% vs -9.8%，领先12.0%），EXACT SCIENCES CORP同比增速更快（23.1% vs 4.5%），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs -6.2%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
Liberty Energy Inc.是北美领先的能源服务供应商，专注为油气运营企业提供水力压裂及完井解决方案，服务覆盖美国主要页岩产区，供应低排放作业设备及定制化支持，帮助提升油气井生产效率。
EXAS vs LBRT — 直观对比
营收规模更大
LBRT
是对方的1.2倍
$878.4M
营收增速更快
EXAS
高出18.6%
4.5%
净利率更高
LBRT
高出12.0%
-9.8%
两年增速更快
EXAS
近两年复合增速
-6.2%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $1.0B |
| 净利润 | $-86.0M | $22.6M |
| 毛利率 | 70.1% | — |
| 营业利润率 | -9.4% | 2.2% |
| 净利率 | -9.8% | 2.2% |
| 营收同比 | 23.1% | 4.5% |
| 净利润同比 | 90.1% | — |
| 每股收益（稀释后） | $-0.45 | $0.14 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASLBRT
| Q1 26 | — | $1.0B | ||
| Q4 25 | $878.4M | $1.0B | ||
| Q3 25 | $850.7M | $947.4M | ||
| Q2 25 | $811.1M | $1.0B | ||
| Q1 25 | $706.8M | $977.5M | ||
| Q4 24 | $713.4M | $943.6M | ||
| Q3 24 | $708.7M | $1.1B | ||
| Q2 24 | $699.3M | $1.2B |
净利润EXASLBRT
| Q1 26 | — | $22.6M | ||
| Q4 25 | $-86.0M | $13.7M | ||
| Q3 25 | $-19.6M | $43.1M | ||
| Q2 25 | $-1.2M | $71.0M | ||
| Q1 25 | $-101.2M | $20.1M | ||
| Q4 24 | $-864.6M | $51.9M | ||
| Q3 24 | $-38.2M | $73.8M | ||
| Q2 24 | $-15.8M | $108.4M |
毛利率EXASLBRT
| Q1 26 | — | — | ||
| Q4 25 | 70.1% | 20.6% | ||
| Q3 25 | 68.6% | 18.7% | ||
| Q2 25 | 69.3% | 22.1% | ||
| Q1 25 | 70.8% | 22.1% | ||
| Q4 24 | 69.0% | 21.4% | ||
| Q3 24 | 69.4% | 26.2% | ||
| Q2 24 | 69.8% | 27.9% |
营业利润率EXASLBRT
| Q1 26 | — | 2.2% | ||
| Q4 25 | -9.4% | 1.9% | ||
| Q3 25 | -3.0% | -0.3% | ||
| Q2 25 | -0.3% | 3.6% | ||
| Q1 25 | -13.6% | 1.9% | ||
| Q4 24 | -122.8% | 2.6% | ||
| Q3 24 | -5.6% | 9.4% | ||
| Q2 24 | -3.8% | 12.2% |
净利率EXASLBRT
| Q1 26 | — | 2.2% | ||
| Q4 25 | -9.8% | 1.3% | ||
| Q3 25 | -2.3% | 4.5% | ||
| Q2 25 | -0.1% | 6.8% | ||
| Q1 25 | -14.3% | 2.1% | ||
| Q4 24 | -121.2% | 5.5% | ||
| Q3 24 | -5.4% | 6.5% | ||
| Q2 24 | -2.3% | 9.3% |
每股收益（稀释后）EXASLBRT
| Q1 26 | — | $0.14 | ||
| Q4 25 | $-0.45 | $0.08 | ||
| Q3 25 | $-0.10 | $0.26 | ||
| Q2 25 | $-0.01 | $0.43 | ||
| Q1 25 | $-0.54 | $0.12 | ||
| Q4 24 | $-4.69 | $0.31 | ||
| Q3 24 | $-0.21 | $0.44 | ||
| Q2 24 | $-0.09 | $0.64 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $699.1M |
| 总债务越低越好 | — | $7.1M |
| 股东权益账面价值 | $2.4B | $1.9B |
| 总资产 | $5.9B | $4.4B |
| 负债/权益比越低杠杆越低 | — | 0.00× |
8季度趋势，按日历期对齐
现金及短期投资EXASLBRT
| Q1 26 | — | $699.1M | ||
| Q4 25 | $964.7M | $27.6M | ||
| Q3 25 | $1.0B | $13.5M | ||
| Q2 25 | $858.4M | $19.6M | ||
| Q1 25 | $786.2M | $24.1M | ||
| Q4 24 | $1.0B | $20.0M | ||
| Q3 24 | $1.0B | $23.0M | ||
| Q2 24 | $946.8M | $30.0M |
总债务EXASLBRT
| Q1 26 | — | $7.1M | ||
| Q4 25 | — | $246.6M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $190.5M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益EXASLBRT
| Q1 26 | — | $1.9B | ||
| Q4 25 | $2.4B | $2.1B | ||
| Q3 25 | $2.5B | $2.1B | ||
| Q2 25 | $2.5B | $2.0B | ||
| Q1 25 | $2.4B | $2.0B | ||
| Q4 24 | $2.4B | $2.0B | ||
| Q3 24 | $3.2B | $2.0B | ||
| Q2 24 | $3.2B | $1.9B |
总资产EXASLBRT
| Q1 26 | — | $4.4B | ||
| Q4 25 | $5.9B | $3.6B | ||
| Q3 25 | $5.9B | $3.5B | ||
| Q2 25 | $5.8B | $3.4B | ||
| Q1 25 | $5.7B | $3.4B | ||
| Q4 24 | $5.9B | $3.3B | ||
| Q3 24 | $6.7B | $3.3B | ||
| Q2 24 | $6.7B | $3.2B |
负债/权益比EXASLBRT
| Q1 26 | — | 0.00× | ||
| Q4 25 | — | 0.12× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.10× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | — |
| 自由现金流经营现金流 - 资本支出 | $120.4M | — |
| 自由现金流率自由现金流/营收 | 13.7% | — |
| 资本支出强度资本支出/营收 | 3.6% | 13.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $356.8M | — |
8季度趋势，按日历期对齐
经营现金流EXASLBRT
| Q1 26 | — | — | ||
| Q4 25 | $151.7M | $195.4M | ||
| Q3 25 | $219.9M | $51.5M | ||
| Q2 25 | $89.0M | $170.6M | ||
| Q1 25 | $30.8M | $192.1M | ||
| Q4 24 | $47.1M | $177.3M | ||
| Q3 24 | $138.7M | $244.5M | ||
| Q2 24 | $107.1M | $248.2M |
自由现金流EXASLBRT
| Q1 26 | — | — | ||
| Q4 25 | $120.4M | $-10.0M | ||
| Q3 25 | $190.0M | $-67.2M | ||
| Q2 25 | $46.7M | $33.1M | ||
| Q1 25 | $-365.0K | $58.2M | ||
| Q4 24 | $10.7M | $-26.2M | ||
| Q3 24 | $112.6M | $77.9M | ||
| Q2 24 | $71.2M | $112.2M |
自由现金流率EXASLBRT
| Q1 26 | — | — | ||
| Q4 25 | 13.7% | -1.0% | ||
| Q3 25 | 22.3% | -7.1% | ||
| Q2 25 | 5.8% | 3.2% | ||
| Q1 25 | -0.1% | 6.0% | ||
| Q4 24 | 1.5% | -2.8% | ||
| Q3 24 | 15.9% | 6.8% | ||
| Q2 24 | 10.2% | 9.7% |
资本支出强度EXASLBRT
| Q1 26 | — | 13.1% | ||
| Q4 25 | 3.6% | 19.8% | ||
| Q3 25 | 3.5% | 12.5% | ||
| Q2 25 | 5.2% | 13.2% | ||
| Q1 25 | 4.4% | 13.7% | ||
| Q4 24 | 5.1% | 21.6% | ||
| Q3 24 | 3.7% | 14.6% | ||
| Q2 24 | 5.1% | 11.7% |
现金转化率EXASLBRT
| Q1 26 | — | — | ||
| Q4 25 | — | 14.28× | ||
| Q3 25 | — | 1.20× | ||
| Q2 25 | — | 2.40× | ||
| Q1 25 | — | 9.55× | ||
| Q4 24 | — | 3.42× | ||
| Q3 24 | — | 3.31× | ||
| Q2 24 | — | 2.29× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
LBRT
暂无分部数据
